Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902437733> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2902437733 endingPage "157" @default.
- W2902437733 startingPage "151" @default.
- W2902437733 abstract "Background: Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TNF-alpha biologic secukinumab (fully human IL-17A-inhibitor) vs adalimumab (TNF-alpha-inhibitor) in the treatment of AS in Finland.Materials and methods: In this model-based budget impact analysis, patients were treated either with secukinumab (150 mg) or adalimumab (40 mg). The number of patients and market share of different biologics were based on national reimbursement registry data. Adalimumab was the most commonly used biologic treatment for AS, and in the base case analysis all adalimumab patients are assumed to switch to secukinumab. Response rates were based on a matching-adjusted indirect comparison between secukinumab and adalimumab. Patients not achieving response were switched to another biologic treatment.Results: Treating AS patients with secukinumab instead of adalimumab leads to potential savings of 18.2 million euros within a 5-year time period. The total costs within the follow-up time were 59.5 million euros and 77.7 million euros with and without secukinumab, respectively. According to sensitivity analyses, a higher adoption rate of secukinumab corresponds to higher potential savings.Conclusions: Secukinumab is a cost-saving treatment option compared with adalimumab in the treatment of AS in Finland. More patients could be treated with a biologic by allocating resources more efficiently." @default.
- W2902437733 created "2018-12-11" @default.
- W2902437733 creator A5011202921 @default.
- W2902437733 creator A5038015674 @default.
- W2902437733 creator A5050624270 @default.
- W2902437733 creator A5066595832 @default.
- W2902437733 date "2018-12-04" @default.
- W2902437733 modified "2023-09-27" @default.
- W2902437733 title "Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis" @default.
- W2902437733 cites W1908131837 @default.
- W2902437733 cites W2067720781 @default.
- W2902437733 cites W2076649515 @default.
- W2902437733 cites W2083621642 @default.
- W2902437733 cites W2091494006 @default.
- W2902437733 cites W2093698914 @default.
- W2902437733 cites W2095185744 @default.
- W2902437733 cites W2166394031 @default.
- W2902437733 cites W2177257388 @default.
- W2902437733 cites W2220479222 @default.
- W2902437733 cites W2472201603 @default.
- W2902437733 cites W2496735567 @default.
- W2902437733 cites W2528269009 @default.
- W2902437733 cites W2572897530 @default.
- W2902437733 cites W2590287407 @default.
- W2902437733 cites W2788504432 @default.
- W2902437733 cites W2898749318 @default.
- W2902437733 cites W4211203343 @default.
- W2902437733 doi "https://doi.org/10.1080/13696998.2018.1551227" @default.
- W2902437733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30474450" @default.
- W2902437733 hasPublicationYear "2018" @default.
- W2902437733 type Work @default.
- W2902437733 sameAs 2902437733 @default.
- W2902437733 citedByCount "5" @default.
- W2902437733 countsByYear W29024377332019 @default.
- W2902437733 countsByYear W29024377332021 @default.
- W2902437733 crossrefType "journal-article" @default.
- W2902437733 hasAuthorship W2902437733A5011202921 @default.
- W2902437733 hasAuthorship W2902437733A5038015674 @default.
- W2902437733 hasAuthorship W2902437733A5050624270 @default.
- W2902437733 hasAuthorship W2902437733A5066595832 @default.
- W2902437733 hasConcept C126322002 @default.
- W2902437733 hasConcept C138885662 @default.
- W2902437733 hasConcept C15708023 @default.
- W2902437733 hasConcept C17991360 @default.
- W2902437733 hasConcept C2776260265 @default.
- W2902437733 hasConcept C2777077863 @default.
- W2902437733 hasConcept C2777138892 @default.
- W2902437733 hasConcept C2777402515 @default.
- W2902437733 hasConcept C2778097690 @default.
- W2902437733 hasConcept C2779786854 @default.
- W2902437733 hasConcept C2780132546 @default.
- W2902437733 hasConcept C71924100 @default.
- W2902437733 hasConceptScore W2902437733C126322002 @default.
- W2902437733 hasConceptScore W2902437733C138885662 @default.
- W2902437733 hasConceptScore W2902437733C15708023 @default.
- W2902437733 hasConceptScore W2902437733C17991360 @default.
- W2902437733 hasConceptScore W2902437733C2776260265 @default.
- W2902437733 hasConceptScore W2902437733C2777077863 @default.
- W2902437733 hasConceptScore W2902437733C2777138892 @default.
- W2902437733 hasConceptScore W2902437733C2777402515 @default.
- W2902437733 hasConceptScore W2902437733C2778097690 @default.
- W2902437733 hasConceptScore W2902437733C2779786854 @default.
- W2902437733 hasConceptScore W2902437733C2780132546 @default.
- W2902437733 hasConceptScore W2902437733C71924100 @default.
- W2902437733 hasIssue "2" @default.
- W2902437733 hasLocation W29024377331 @default.
- W2902437733 hasLocation W29024377332 @default.
- W2902437733 hasOpenAccess W2902437733 @default.
- W2902437733 hasPrimaryLocation W29024377331 @default.
- W2902437733 hasRelatedWork W1491449491 @default.
- W2902437733 hasRelatedWork W2052900499 @default.
- W2902437733 hasRelatedWork W2116773863 @default.
- W2902437733 hasRelatedWork W2390905470 @default.
- W2902437733 hasRelatedWork W2606290205 @default.
- W2902437733 hasRelatedWork W2765460113 @default.
- W2902437733 hasRelatedWork W2905601990 @default.
- W2902437733 hasRelatedWork W2906115491 @default.
- W2902437733 hasRelatedWork W2994755740 @default.
- W2902437733 hasRelatedWork W4249769707 @default.
- W2902437733 hasVolume "22" @default.
- W2902437733 isParatext "false" @default.
- W2902437733 isRetracted "false" @default.
- W2902437733 magId "2902437733" @default.
- W2902437733 workType "article" @default.